There are benefits of smaller companies teaming up with larger commercial partners to leverage the latter's established sales channels, but the relationship can hit the rocks if the larger partner is having to navigate itself through troubled waters.
This looks to be the case for Respicardia Inc., which suspended an EU post-market study of its remedē neuromodulation...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?